Biota partner to market
Monday, 30 March, 2009
Japanese biopharma Daiichi Sankyo, which co-owns a long-acting neuraminidase inhibitor for influenza with Australia’s Biota, has applied to manufacture and market the drug in Japan.
The contract depends on the successful completion of Phase III trials in Asia and on obtaining regulatory approval.
The trials have completed patient enrolment with results expected mid-year, Biota said in a statement.
The drug, CS-8958, is a long-acting flu drug which needs less frequent dosing than current neuraminidase inhibitors such as Roche’s oseltamivir (Tamiflu) and Biota’s own zanamivir (Relenza), which is marketed by GSK.
Daiichi Sankyo has rights to the drug in Japan, but Biota said all other key markets are available for licensing by the partners.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
